These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20927697)

  • 61. Should the CATIE study be a wake-up call?
    Ragins M
    Psychiatr Serv; 2005 Dec; 56(12):1489. PubMed ID: 16339608
    [No Abstract]   [Full Text] [Related]  

  • 62. Cross-cultural study of schizophrenia.
    Taleb M; Rouillon F; Petitjean F; Gorwood P
    Psychopathology; 1996; 29(2):85-94. PubMed ID: 8861512
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Therapeutic guidelines in schizophrenias].
    Petitjean F
    Encephale; 2006 Oct; 32(5 Pt 3):S855-7. PubMed ID: 17119486
    [No Abstract]   [Full Text] [Related]  

  • 64. Remission in schizophrenia - What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression.
    Schennach R; Obermeier M; Spellmann I; Seemüller F; Musil R; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Bauer M; Adli M; Zeiler J; Bender W; Kronmüller KT; Ising M; Brieger P; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ; Riedel M
    Schizophr Res; 2019 Jul; 209():185-192. PubMed ID: 31138482
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Antipsychotic effects of ceruletide (caerulein) on chronic schizophrenia.
    Moroji T; Watanabe N; Aoki N; Itoh S
    Arch Gen Psychiatry; 1982 Apr; 39(4):485-6. PubMed ID: 7039550
    [No Abstract]   [Full Text] [Related]  

  • 66. Schizophrenia--falling incidence and better outcome?
    Harrison G; Mason P
    Br J Psychiatry; 1993 Oct; 163():535-41. PubMed ID: 7902767
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid.
    Puri BK; Richardson AJ
    Arch Gen Psychiatry; 1998 Feb; 55(2):188-9. PubMed ID: 9477938
    [No Abstract]   [Full Text] [Related]  

  • 68. An integrated eye movement score as a neurophysiological marker of schizophrenia.
    Miura K; Hashimoto R; Fujimoto M; Yamamori H; Yasuda Y; Ohi K; Umeda-Yano S; Fukunaga M; Iwase M; Takeda M
    Schizophr Res; 2014 Dec; 160(1-3):228-9. PubMed ID: 25458574
    [No Abstract]   [Full Text] [Related]  

  • 69. Factors associated with the prodromal progression of schizophrenia that influence the course of the illness.
    Bota RG; Sagduyu K; Munro JS
    CNS Spectr; 2005 Dec; 10(12):937-42. PubMed ID: 16344830
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Negative symptoms in schizophrenia--the remarkable impact of inclusion definitions in clinical trials and their consequences.
    Rabinowitz J; Werbeloff N; Caers I; Mandel FS; Stauffer V; Menard F; Kinon BJ; Kapur S
    Schizophr Res; 2013 Nov; 150(2-3):334-8. PubMed ID: 23815975
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group.
    Howard R; Rabins PV; Seeman MV; Jeste DV
    Am J Psychiatry; 2000 Feb; 157(2):172-8. PubMed ID: 10671383
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Repetitive behaviors in schizophrenic patients admitted to an acute-care unit: a replicative study.
    Alexander RC; Lowenkopf T; Certa KM; Luchins DJ
    J Nerv Ment Dis; 1993 Dec; 181(12):763-4. PubMed ID: 8254329
    [No Abstract]   [Full Text] [Related]  

  • 73. Clinical trials and tribulations: implementation processes in schizophrenia research outcome.
    Mason SE; Bermanzohn PC; Siris SG
    Psychiatry; 1998; 61(4):288-301. PubMed ID: 9919624
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Re: The use of placebos in clinical trials for acute schizophrenia.
    Zipursky RB
    Can J Psychiatry; 1995 Sep; 40(7):425-6. PubMed ID: 8548724
    [No Abstract]   [Full Text] [Related]  

  • 75. Critical study of the Organic Integrity Test as a diagnostic and therapeutic index in schizophrenia.
    Kay SR; Gang RG
    Percept Mot Skills; 1973 Dec; 37(3):827-33. PubMed ID: 4587547
    [No Abstract]   [Full Text] [Related]  

  • 76. Response to Kujawa et al. letter-to-the-editor.
    Sethuraman G; Taylor CC; Enerson M; Dunayevich E
    Schizophr Res; 2006 May; 84(1):172-3. PubMed ID: 16563702
    [No Abstract]   [Full Text] [Related]  

  • 77. Associative learning in acutely ill and recovered schizophrenic patients.
    O'Carroll RE
    Schizophr Res; 1995 May; 15(3):299-301. PubMed ID: 7632628
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?
    Alphs L; Benedetti F; Fleischhacker WW; Kane JM
    Int J Neuropsychopharmacol; 2012 Aug; 15(7):1003-14. PubMed ID: 22217384
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Assessment of the notion of remission in schizophrenia].
    Azorin JM
    Encephale; 2005 Dec; 31 Pt 2():S7-10. PubMed ID: 16462626
    [No Abstract]   [Full Text] [Related]  

  • 80. Assessing the efficacy of treatments for the deficit syndrome of schizophrenia.
    Kirkpatrick B; Kopelowicz A; Buchanan RW; Carpenter WT
    Neuropsychopharmacology; 2000 Mar; 22(3):303-10. PubMed ID: 10693158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.